Objective: To analyse the effectiveness and safety of cyclosporin A (CsA) in the treatment of steroid dependent nephrotic syndrome (SDNS) in childhood.
Introduction
Children with steroid dependent nephrotic syndrome (SDNS) usually experience steroid toxicity as they need to be maintained on steroids for prolonged periods 1 . Alkylating agents like cyclophosphamide and chlorambucil have been used as adjuncts to corticosteroid therapy for sustaining remission in patients with frequently relapsing nephrotic syndrome. Although efficacy of these drugs is well established in patients without steroid dependence, its effects have been rather variable in steroid dependent patients 2 . Moreover, the potential side effects, particularly risks of opportunistic infections, sterility in men and development of future malignancies have limited their use in SDNS 3, 4 .
Idiopathic nephrotic syndrome (INS) is considered an immunological disorder, a disorder of T cell function.
It is now believed that a disturbance in the Th1 and Th2 immune mechanisms, mediated by cytokines and lymphokines, are responsible in both generation of the disease and its relapse 5 . In 1985, some reasoned that the postulated immunologic mechanism of INS (i.e. secretion of a cationising lymphokine by T lymphocytes resulting in proteinuria) would be responsive to treatment with cyclosporin A (CsA), given the mode of action of this new immunosuppressive agent 6, 7 .
There is consistent evidence, from both experimental and human studies, that the highly lipophilic CsA molecule diminishes or abolishes proteinuria by two mechanisms 8 . The first is its immunosuppressive action, in which CsA prevents the release of interleukin-2 and interferon and possibly other lymphokines from activated T cells, suppressing glomerular permeability 9 . The second mechanism is a direct action on the selectivity of the glomerular basement membrane, especially on the electromechanical barrier which repulses the anionic albumin molecules [10] [11] [12] .
CsA therapy is well recognised regarding its steroid sparing effect in steroid dependant patients and is responsible for maintaining remission in more than 75% of patients with SDNS even after discontinuation of steroids 1, 13, 14 . Furthermore, it has been shown to be effective in inducing remission in steroid resistant INS 15, 16 . CsA is associated with a plethora of side effects such as hypertension, nephrotoxicity hypertrichosis, gum hyperplasia, gastrointestinal disturbances and tremor 17, 18 . The effects of CsA therapy on Sri Lankan children have not been documented in the published literature.
Objective
To analyse the effectiveness and safety of CsA in the treatment of SDNS in childhood
Patients and Methods
Sequential children presenting with SDNS to the Nephrotic Syndrome Clinic at Teaching Hospital, Peradeniya, a tertiary referral centre in Sri Lanka, from 2004, who fulfilled the following inclusion criteria were enrolled: Two or more consecutive relapses while receiving over 1mg/kg of prednisolone on alternate days, with normal renal function and who had received at least one course of cyclophosphamide and had a renal biopsy. They were treated with CsA 3-5 mg/kg/day aiming to achieve a 12 hour trough level between 75-100ng/ml. All patients were requested to test and record the urinary protein excretion daily and were reviewed on a monthly basis. On each review the patients were carefully examined for side-effects of CsA such as hirsutism, hypertension, gingival hypertrophy and opportunistic infections. The biochemical evaluation of the nephrotic state, liver and renal functions were made by serial assessment of urinary protein excretion, serum albumin, serum cholesterol, serum alanine transaminase and serum creatinine performed at 3 monthly intervals. Primary end points of the study were to analyse the rise of serum albumin, reduction of serum cholesterol and reduction of maintenance dose of prednisolone at 6 months of therapy. Additionally, in order to evaluate the safety profile of CsA therapy analysis was made on the side effects of CsA. Statistical analysis was performed using paired t-test. Criteria for diagnosis of nephrotic syndrome, remission, relapse, and steroid dependence, were as per definitions used by the International Study of Kidney Disease in Children 19, 20 .
Results
Over a period of 5 years 48 children who satisfied the inclusion criteria were recruited to the study. CsA therapy was discontinued in two patients who had evidence of nephrotoxicity within 6 months of therapy and they were excluded from the analysis for effectiveness. Of the remaining 46 thirty one (70%) were boys. Hypertension needing antihypertensive treatment was seen in 26 (57%) of the 46 patients. Two (4%) patients had significant elevations of serum creatinine needing discontinuation of treatment. Significant hirsutism was noted in 37 (80%) patients. All patients had normal liver enzymes and opportunistic infections were not encountered in this cohort of patients.
Discussion
A cardinal feature of INS is the tendency to relapse. Relapses generally respond to steroids much better than the initial episode. Unlike the initial treatment regimen, more intensive treatment of relapses with higher doses or longer duration of prednisolone has little or no effect on the subsequent relapse rate. Children with a frequently relapsing disease or steroid dependent disease ideally need individualised treatment. Although there is no data on the merits of long-term maintenance prednisolone as opposed to repeated standard relapse treatment, most favour the former approach 19, 21 . The dose of prednisolone should be titrated to the lowest that is sufficient to maintain remission in order to minimise steroid toxicity. Most school age children can tolerate 0.5-0.6 mg/kg/body weight on alternate days, while preschool children may tolerate up to 1mg/kg/body weight on alternate days. The duration of alternate day prednisolone therapy should be for a minimum of 3-6 months, although a selected group of children may benefit from longer duration of treatment 21 .
Steroid toxicity is of major concern to children with INS and their families. There is a positive correlation between toxicity and cumulative dose of steroids in children with SSNS 21 . Obesity, hirsutism, hypertension, psychological and behavioural disturbances are usually reversible after cessation of steroid therapy. However, striae and cataracts are irreversible. Moreover, prolonged steroid therapy is associated with significant growth impairment 2 .
In SDNS CsA is generally reserved for children who demonstrate steroid dependence following a course of cyclophosphamide. However CsA is now increasingly used in preference to cyclophosphamide in children approaching puberty, especially in boys, who are more vulnerable to gonadal toxicity and in whom the disease may be nearing the end of its natural history, obviating the need for prolonged immunosuppression. The usual dose of CsA is 3-5mg/kg/day to achieve a 12 hour trough blood level of 50 -150ng/ml, usually for up to a year. The optimal duration of CsA therapy, however, is unclear. Unlike cyclophosphamide, the relapse rates are high when the drug is discontinued 19 . Sustained remissions have been achieved with continuous CsA therapy for 5 years 19 but the prolonged use of CsA necessitates regular and frequent monitoring of blood levels at least 3 monthly when stable, and regular estimation of glomerular filtration rate because of its potential nephrotoxicity. Moreover, prolonged therapy with CsA may be associated with a long-term risk of lymphoma 19, 22 and thus should be considered only for selected patients with SSNS who are difficult to control.
Most of the evidence on CsA therapy on INS has emerged from the northern hemisphere involving mostly Caucasian children. Its use in Asian children is limited to a few studies involving small numbers. There are no studies in the published literature on the use of CsA in Sri Lankan children with INS. As per inclusion criteria of this study, patients with severe forms of SDNS who were already treated with cyclophosphamide and relapsing on very high doses of prednisolone were recruited. The results of this study reveal that the use of CsA in combination with prednisolone is effective in maintaining sustained remission in severe forms of SDNS with a significant steroid sparing effect. Biochemical evaluation revealed a significant rise in serum albumin and a significant reduction in the serum cholesterol level at six months of therapy which confirms the stability of the disease. The ability to reduce the maintenance dose of prednisolone in over 80% of patients indicates its potency as a steroid sparing agent.
Notable side effects were hypertension and hirsutism. Although the serum creatinine was significantly raised only in the 2 patients who were withdrawn from the study, this does not rule out chronic CsA nephrotoxicity which can only be documented by renal biopsy 22 and most recommend a renal biopsy at the completion of 2 years of therapy.
Conclusions
• Treatment with CsA in combination with lowdose prednisolone is highly effective in maintaining complete remission in difficult SDNS in childhood.
• Side effects encountered were reversible nephrotoxicity (4%), hypertension (57%) and hirsutism (80%).
• There was no significant difference in the response rate according to the different histological types. Thus a renal biopsy is not essential when commencing CsA therapy for steroid sensitive but dependent patients.
